Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study

Karen Anderson, Jennifer E. Gerber, Gypsyamber D'Souza, Sara I. Pai, Julia N. Cheng, Rizwan Alam, Sailaja Kesiraju, Diego Chowell, Neil D. Gross, Robert Haddad, Maura L. Gillison, Marshall Posner

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.

    Original languageEnglish (US)
    Pages (from-to)751-758
    Number of pages8
    JournalOral Oncology
    Volume51
    Issue number8
    DOIs
    StatePublished - 2015

    Fingerprint

    Oropharyngeal Neoplasms
    Healthy Volunteers
    Antigens
    Immunoglobulin G
    Serum
    Virus Integration
    Human papillomavirus 16
    Sexual Partners
    Serology
    Viral Load
    Sexual Behavior
    Multicenter Studies
    Antibody Formation
    Volunteers
    Linear Models
    Enzyme-Linked Immunosorbent Assay
    Demography
    Antibodies

    Keywords

    • Antibodies
    • Biomarker
    • HPV
    • Oropharyngeal cancer
    • Serology

    ASJC Scopus subject areas

    • Oncology
    • Oral Surgery
    • Cancer Research

    Cite this

    Biologic predictors of serologic responses to HPV in oropharyngeal cancer : The HOTSPOT study. / Anderson, Karen; Gerber, Jennifer E.; D'Souza, Gypsyamber; Pai, Sara I.; Cheng, Julia N.; Alam, Rizwan; Kesiraju, Sailaja; Chowell, Diego; Gross, Neil D.; Haddad, Robert; Gillison, Maura L.; Posner, Marshall.

    In: Oral Oncology, Vol. 51, No. 8, 2015, p. 751-758.

    Research output: Contribution to journalArticle

    Anderson, K, Gerber, JE, D'Souza, G, Pai, SI, Cheng, JN, Alam, R, Kesiraju, S, Chowell, D, Gross, ND, Haddad, R, Gillison, ML & Posner, M 2015, 'Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study' Oral Oncology, vol. 51, no. 8, pp. 751-758. https://doi.org/10.1016/j.oraloncology.2015.05.007
    Anderson, Karen ; Gerber, Jennifer E. ; D'Souza, Gypsyamber ; Pai, Sara I. ; Cheng, Julia N. ; Alam, Rizwan ; Kesiraju, Sailaja ; Chowell, Diego ; Gross, Neil D. ; Haddad, Robert ; Gillison, Maura L. ; Posner, Marshall. / Biologic predictors of serologic responses to HPV in oropharyngeal cancer : The HOTSPOT study. In: Oral Oncology. 2015 ; Vol. 51, No. 8. pp. 751-758.
    @article{9c4e56c313214b9bb1601a334689d3ce,
    title = "Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study",
    abstract = "Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90{\%}), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6{\%} of cases, 0{\%} of partners and 7.4{\%} of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.",
    keywords = "Antibodies, Biomarker, HPV, Oropharyngeal cancer, Serology",
    author = "Karen Anderson and Gerber, {Jennifer E.} and Gypsyamber D'Souza and Pai, {Sara I.} and Cheng, {Julia N.} and Rizwan Alam and Sailaja Kesiraju and Diego Chowell and Gross, {Neil D.} and Robert Haddad and Gillison, {Maura L.} and Marshall Posner",
    year = "2015",
    doi = "10.1016/j.oraloncology.2015.05.007",
    language = "English (US)",
    volume = "51",
    pages = "751--758",
    journal = "Oral Oncology",
    issn = "1368-8375",
    publisher = "Elsevier Limited",
    number = "8",

    }

    TY - JOUR

    T1 - Biologic predictors of serologic responses to HPV in oropharyngeal cancer

    T2 - The HOTSPOT study

    AU - Anderson, Karen

    AU - Gerber, Jennifer E.

    AU - D'Souza, Gypsyamber

    AU - Pai, Sara I.

    AU - Cheng, Julia N.

    AU - Alam, Rizwan

    AU - Kesiraju, Sailaja

    AU - Chowell, Diego

    AU - Gross, Neil D.

    AU - Haddad, Robert

    AU - Gillison, Maura L.

    AU - Posner, Marshall

    PY - 2015

    Y1 - 2015

    N2 - Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.

    AB - Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.

    KW - Antibodies

    KW - Biomarker

    KW - HPV

    KW - Oropharyngeal cancer

    KW - Serology

    UR - http://www.scopus.com/inward/record.url?scp=84942827166&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84942827166&partnerID=8YFLogxK

    U2 - 10.1016/j.oraloncology.2015.05.007

    DO - 10.1016/j.oraloncology.2015.05.007

    M3 - Article

    VL - 51

    SP - 751

    EP - 758

    JO - Oral Oncology

    JF - Oral Oncology

    SN - 1368-8375

    IS - 8

    ER -